Form 4: Vistagen Therapeutics CEO Reports Stock Option Grant

Vistagen Therapeutics CEO Shawn Singh received a grant of stock options totaling 75,000 shares with an exercise price of $0.5358.

Summary

• Shawn Singh, President and CEO of Vistagen Therapeutics, Inc., was granted stock options on April 7, 2026.
• The grant includes 3,732 Incentive Stock Options and 71,268 Non-Qualified Stock Options.
• The exercise price for all options is $0.5358 per share.
• These options are part of the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan.
• Vesting commences six months after the grant date, with 25% vesting every six months thereafter, fully vesting two years from the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard executive stock option grant without immediate financial impact or significant strategic news.

Positives

• CEO receives stock options, aligning management's interests with shareholders.
• The option grant is structured with a vesting schedule, encouraging long-term commitment.
• The exercise price is relatively low, potentially offering significant upside if the stock price increases.

Risks

• The value of the stock options is entirely dependent on the future performance of Vistagen Therapeutics' stock price.
• If the company's stock price does not exceed the exercise price of $0.5358, the options will expire worthless.

Future Outlook

The future outlook for the stock options is contingent on the company's performance and stock price appreciation, with full vesting occurring two years from the grant date.

Industry Context

StockSavvy.ai notes that grants of stock options to senior management are a common practice in the biotechnology and pharmaceutical sectors, serving as a tool for executive compensation and to incentivize performance and long-term value creation.

Stakeholder Impact

• Shareholders: The grant aligns CEO incentives with shareholder value, but the actual impact depends on future stock performance.
• Employees: May indicate a broader equity incentive culture within the company.
• Management: CEO's compensation is directly tied to company performance through these options.

Next Steps

• Options will vest in installments over two years from the grant date.
• Reporting person will continue to comply with Section 16 reporting requirements.

Key Dates

Keywords

Vistagen Therapeutics, Shawn Singh, stock options, equity incentive plan, SEC Form 4, insider trading, executive compensation, biotechnology